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Background. Cell salvage in obstetrics is still a controversial subject and has yet to be fully
embraced. The aim of this exploratory study was to measure amniotic ﬂuid (AF), heparin,
and fetal red cell contamination of washed ﬁltered salvaged maternal blood and to investigate
differences based on the number of suction devices used.
Methods. Patients undergoing elective Caesarean section were assigned alternately to one of
two groups. In Group 1, all blood and AF was collected with one suction. In Group 2, AF was
aspirated to waste with a second separate suction device before collection of any blood.
Results. In both groups, alpha-fetoprotein (AFP), squames cells, and heparin were signiﬁcantly
reduced (P,0.001) by the washing and ﬁltering process. Mean AFP levels post-ﬁltration were
2.58 IU ml
21 in Group 1 and 3.53 IU ml
21 in Group 2. Squames cells were completely
removed in all but two cases. Fetal red blood cells were still present in the ﬁnal product, range
0.13–4.35%. In Group 1, haemoglobin and haematocrit were higher than in Group 2, with
lower white blood cell, AFP, and fetal red cell counts.
Conclusions. This study adds to the growing body of evidence that there is little or no
possibility for AF contamination to enter the re-infusion system when used in conjunction with
a leucodepletion ﬁlter.
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The use of cell salvage in obstetrics remains controversial.
There is a concern of potential contamination of the
salvaged blood with amniotic ﬂuid (AF), which may cause
AF embolus (anaphylactoid syndrome of pregnancy),
1 and
the risk of alloimmunization of the mother with any fetal
red blood cells aspirated.
Previous studies investigated the use of cell salvage
in obstetrics and focused on the feasibility of the
washing process in removing potential contaminants.
After the use of a leucodepletion ﬁlter in cancer
surgery, these ﬁlters were introduced into obstetric prac-
tice.
1 A later study using a newer advanced model
demonstrated complete removal or a further reduction in
contaminants by these ﬁlters.
2 Along with these results
and later reports, the National Institute of Health and
Clinical Excellence (NICE) published guidelines in
2005 suggesting that these ﬁlters can be considered for
use in obstetrics.
3
A common assumption was that two suction devices
should be used, with as much AF aspirated to waste before
any lost blood is collected.
14
Although current evidence supports the use of cell
salvage in obstetrics, a recent review suggested that more
clinical data are required to add to this evidence and make
the use of cell salvage more commonplace in obstetrics.
4
The aim of the study was to add results to the current
clinical evidence to support the use of cell salvage. We
measured AF and fetal red cell contamination, and residual
heparin levels of washed salvaged maternal blood when
using either one or two suction devices, ﬁltering the
washed product through a leucodepletion ﬁlter for cell
salvage (RS1 VAE PALL
w Medical).
# 2008 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
British Journal of Anaesthesia 101 (2): 225–9 (2008)
doi:10.1093/bja/aen135 Advance Access publication May 30, 2008Methods
Information to perform power analysis and produce a well-
designed prospective study is lacking due to the limited data
available.
4 This study was set up as an exploratory study to
investigate the safety and feasibility of cell salvage in obste-
trics. Ethics Committee opinion was sought, but approval
was not required. The sample size was dependent on the
number of patients accessible over a set time period.
Written informed consent was obtained from 34 patients
undergoing elective lower segment Caesarean section at the
Royal Cornwall Hospital over a 4 month period. Patients
were alternatively assigned to one of two groups before
surgery. Group 1 (n¼17) involved only one suction where all
AF and blood was collected into the cell salvage machine,
with Group 2 (n¼17) using a second suction to aspirate as
much AF to waste before any lost blood was collected.
All patients had a spinal anaesthetic apart from one who
had an epidural top up; all spinals were performed using a
Whitacre 25 gauge needle, with hyperbaric bupivacaine
0.5% and morphine 0.1 mg plus in some cases fentanyl
10–20 mg. In two cases, spinals had to be performed
twice due to incomplete blocks and one was converted to
a general anaesthetic.
During the surgical procedure, any blood lost was
salvaged into a Dideco Electa Autotransfusion Cell
Separator (Sorin Group, Milan, Italy). Aspirated blood was
mixed with heparin 30 000 IU litre
21 of saline. Suction
was set at 100–150 mm Hg with a prime at 100 ml min
21
and wash volumes of 900 ml on a continuing wash at
100 ml min
21. The set was emptied at 150 ml min
21.
A 55 ml Latham bowl was used in all cases. In addition,
any swabs from the surgical procedure were soaked in
1 litre of saline and ‘compressed’ at the end of case and
solution aspirated, maximizing red cell collection.
Processed washed blood was then gravity run through
a Pall RS1 VAE leucodepletion ﬁlter (Pall Medical,
Portsmouth, UK) into another re-infusion bag.
Pre-wash samples were taken from the collection reser-
voir, and post-wash and post-ﬁltration samples were taken
from the re-infusion packs, which were inverted gently
several times to ensure even mixing before sampling.
The cell salvage machine use and sampling, in all
cases, was performed by the same member of staff.
Pre-wash, post-wash, and post-ﬁltration samples from
both groups were tested for markers of AF contamination
and heparin levels. Post-ﬁltration samples were also tested
to quantify any fetal red blood cells.
Six millilitres of blood were collected into a specimen
tube and processed for alpha-fetoprotein (AFP) on an
E170 Modular Analytics Analyser (Roche Diagnostics,
Basel, Switzerland).
Four millilitres of blood were collected and centrifuged
at 1600g for 5 min and processed for heparin levels on an
Instrumentation Laboratory Futura Advance Coagulometer
(Instrumentation Laboratory, MA, USA).
Six millilitres of blood were collected for fetal squames
cell levels. After centrifugation at 1200g for 5 min, one
part plasma was mixed with three parts Cytolyt Solution
(Cytyc Corporation, West Sussex, UK). Vials were then
centrifuged at 1200g for 5 min and supernatant discarded.
Two to three drops of the cell bullet were then transferred
to 20 ml PreservCyt Solution (Cytyc Corporation) and pro-
cessed on a ThinPrep
w2000 Processor (Cytyc Corporation)
using blue-box non-gynae ﬁlters (Cytyc Corporation), gen-
erating one alcohol-ﬁxed slide per sample. Slides were
stained using the Papanicolaou technique. To avoid any
potential carryover, pre-wash, post-wash, and post-
ﬁltration slides were stained separately using fresh
reagents. Each slide was then examined under light
microscopy for presence of fetal squames cells, with the
whole slide being counted to exclude any variables, giving
a result of number of cells per slide.
Two millilitres of blood were collected into EDTA for a
full blood count to provide haemoglobin (Hb), haematocrit
(HCT), and white blood cell (WBC) levels on a Bayer
Advia 120 analyser (Bayer, Newbury, UK).
Post-ﬁltration samples were also tested for fetal red
blood cell quantiﬁcation. Five millilitres of blood were
collected into EDTA and processed with a monoclonal
antibody to fetal Hb (IQProducts, Groningen, The
Netherlands), with a Becton Dickinson FACSCalibur (NJ,
USA) ﬂow cytometer at 540 nm. Note: it was planed to
perform all 34 cases for fetal red cells by ﬂow cytometry,
but due to unforeseen circumstances, the ﬁrst seven cases
were analysed using the Kleihauer–Betke technique.
Pre- and post-wash samples and post-wash and post-
ﬁltration samples were compared. Parametric data were
analysed using a paired t-test, and non-parametric data
analysed using a one-sample Wilcoxon test. P,0.05 was
considered statistically signiﬁcant. The observed power of
the study was calculated after the collection of the data.
Results
Mean (SD) (range) age of patients in Group 1 was 32.1
(19–46) yr, and weight 82.7 (16.2) kg. In Group 2, the
age was 32.1 (24–41) yr and body weight 82.4 (12.6) kg.
Table 1 gives the reason for Caesarean section along with
any coexisting diseases as shown in Table 2.
Table 1 Reasons for Caesarean section
Reason Number
Previous section 23
Twins IVF 2
Back injury/pain 2
Breech 2
Failure to progress/Category 3 1
IUGR 1
Polyartetitisnodosa 1
Raised BP/pregnancy-induced hypertension 1
Placenta praevia 1
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Four cases did not lose enough blood to obtain post-
ﬁltration samples (one from Group 1 and three from
Group 2), with three further cases having partially ﬁlled
bowls. A partial bowl was deﬁned as a bowl that was not
completely ﬁlled in the automatic mode of the cell salvage
machine. These three bowls provided erroneous post-
ﬁltration results and, therefore, were excluded from analy-
sis. The ﬁnal blood product in these cases (one from
Group 1 and two from Group 2) had a reduced Hb level of
7.1–10.3 g dl
21 and HCT of 21–31%, with a higher level
of fetal red blood cells: 10.5% compared with 1.51%.
Apart from fetal red blood cells in one case (Group 2),
the values for Hb, HCT, and fetal red blood cells all were
considerably above the upper 95% conﬁdence limit for the
full bowls.
The collected blood volume from Group 1 [1782 (354)
ml] was slightly higher than that collected in Group 2
[1497 (562) ml], but the difference was not statistically
signiﬁcant (P¼0.14). Similarly, on average, the red blood
cell volume was higher in Group 1 [168 (77) ml] than in
Group 2 [135 (94) ml], but again the difference was not
statistically signiﬁcant (P¼0.30).
Table 3 shows the mean Hb, AFP, squames cells, and
fetal red cell levels in the groups, along with statistical
analysis.
Dependent on the manufacturer, the reference range for
AFP is up to 10–15 IU ml
21. The post-wash levels were
signiﬁcantly reduced (P,0.001) with no further reduction
seen post-ﬁltration (P¼0.996). On average, there was a
98.7% reduction of pre-wash levels by the washing stage.
Mean heparin levels pre-wash were 1.33 IU ml
21 (95%
CI 0.91–1.75 IU ml
21) in Group 1 and 1.44 IU ml
21
(95% CI 0.82–2.05 IU ml
21) in Group 2. Levels were
reduced by 100% in both the groups (P,0.001) by the
washing stage with no heparin being detected post-wash or
post-ﬁltration in all 34 cases.
Fetal squames cells were present in 12 out of 34 cases
(six from each group) pre-wash, present in all post-wash
samples, with a signiﬁcant reduction post-ﬁltration
(P,0.001). Squames were present in two post-ﬁltration
samples, with two cells seen in each case. Both cases were
from Group 1. Pre-wash samples were heavily diluted with
AF and heparinized saline from surgery explaining why 22
samples were negative.
The mean percentage fetal red cells post-ﬁltration from
all cases (both groups) was 1.51% (95% CI 0.98–2.05),
with a range of 0.13–4.35%. The ﬁrst seven cases (three
from Group 1 and four from Group 2) performed by the
Kleihauer technique generated a mean 1.72% (95% CI
20.65 to 4.08), whereas the remaining cases performed by
ﬂow cytometry resulted in mean 1.47% (95% CI 0.92–
2.01).
Discussion
This study has shown the efﬁciency of the washing stage
of the cell salvage machine, when used in combination
with a leucodepletion ﬁlter, in signiﬁcantly reducing levels
of AF contaminants.
AFP was signiﬁcantly reduced post-wash to levels well
within the normal range for the general population, con-
ﬁrming the results from previous studies.
156
During the study, the amount of heparin used was higher
than with other surgical disciplines due to the hypercoagul-
able state of pregnancy. It would be expected that pre-wash
samples were heavily contaminated with heparin, and this
was conﬁrmed during the study. It has been previously
reported that residual levels of heparin remain in salvaged
blood,
4 but we have now demonstrated the complete
removal of heparin by the washing process in all 34 cases.
The role of fetal squames cells in AF embolus is still
debated. In one study,
1 fetal squames cells were still
present even with the additional step of ﬁltering the
washed blood through a leucodepletion ﬁlter, with only
Table 2 Coexisting diseases
Co-morbidity Number
Smoker 5
Diabetic 2
Asthma 2
Epilepsy 1
Protein S deﬁciency 1
Polyartetitisnodosa 1
Table 3 Analysis and comparison for Group 1 and Group 2. AFP, alpha-fetoprotein. Values are mean (95% CI). *We acknowledge that the observed power
results are low; this, however, is one of the largest studies to date in the obstetric setting.
†Mean HCT post-ﬁltration was 45% in Group 1 and 42% in Group 2
Group 1 Group 2 P-value Observed power*
AFP pre-wash (IU ml
21) 253.72 (183.64–323.80) 381.60 (193.63–569.57) 0.19 0.26
AFP post-wash (IU ml
21) 2.71 (0.80–4.62) 3.14 (1.45–4.83) 0.72 0.06
AFP post-ﬁltration (IU ml
21) 2.58 (0.54–4.62) 3.53 (1.29–5.76) 0.51 0.10
Hb pre-wash (g dl
21) 2.14 (1.52–2.75) 1.83 (1.17–2.50) 0.48 0.11
Hb post-wash (g dl
21) 16.95 (16.28–17.62) 16.20 (15.26–17.14) 0.18 0.27
Hb post-ﬁltration
† (g dl
21) 15.77 (15.07–16.47) 14.74 (13.70–15.78) 0.17 0.27
Squames cells pre-wash (cells per slide) 1.12 (20.02 to 2.25) 0.94 (0.01–1.74) 0.80 0.06
Squames cells post-wash (cells per slide) 34.59 (10.89–58.28) 43.71 (14.42–73.00) 0.61 0.08
Squames cells post-ﬁltration (cells per slide) 0.27 (20.11 to 0.66) 0 0.18 0.26
Fetal red blood cells (%) 1.34 (0.56–2.12) 1.76 (0.95–2.57) 0.43 0.12
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Advanced ﬁlters may reduce this contamination.
2
Of the 27 cases in our study, only two were positive post-
ﬁltration with two cells seen in each slide for each case.
These were found when one suction was used. However, it
is difﬁcult to differentiate between fetal and adult squames
cells. There is no evidence to show that fetal squames cells
routinely enter the maternal circulation,
7 and so the signiﬁ-
cance of this contamination is difﬁcult to quantify and in
fact may have no clinical signiﬁcance.
Fetal red blood cells were still present in the ﬁnal
product, consistent with previous studies,
26and so could be
signiﬁcant in cases of red cell antigen incompatibilities
between the mother and fetus. Rh(D) incompatibilities,
although clinically signiﬁcant, are generally avoided by
routine prophylactic anti-D treatment throughout the preg-
nancy. However, fetal hyperbilirubinaemia and anaemia in
future pregnancies can occur when antibodies have been
formed to other red cell antigen incompatibilities. Examples
of other clinically relevant antibodies that have been impli-
cated in haemolytic disease of the newborn include anti-K,
anti-c, anti-Fy(a), and anti-Jk(a).
8 Nevertheless, it must be
appreciated that there is still a risk of alloimmunization of
the mother either from transfusion of allogenic blood or a
sensitizing event during pregnancy.
Current treatment of obstetric haemorrhage is with allo-
genic blood transfusion; however, there are concerns with
allogenic blood. To date, there have been four conﬁrmed
cases of vCJD transmission via allogeneic blood, conﬁrm-
ing that vCJD can be transmitted through blood
transfusion.
9
These potential risks of transfusion and reduction in
availability of blood make it important to establish the use
of cell salvage in obstetrics. It has been shown in more
than 400 documented cases where cell salvaged blood has
been returned to mothers with no signiﬁcant adverse
results.
41 01 1Several key studies have commented on the
use of cell salvage.
12–14
This current study is one of the largest to date, with
results that add to the growing body of evidence, showing
there is little or no possibility for AF contamination to
enter the re-infusion system, when used in conjunction
with a leucodepletion ﬁlter. The role of the leucodepletion
ﬁlter in this study has conﬁrmed that it is required to
remove AF contamination in cell salvage. WBC, platelets,
and squames cells were still present post-wash but were
signiﬁcantly reduced by the ﬁlter. Whether the squames
are of fetal or maternal origin is perhaps irrelevant as the
ﬁlters have shown that they can remove both. As expected,
AFP and heparin levels were not reduced by the ﬁlter, but
heparin was completely removed in the washing process.
Regarding cell salvage in obstetrics, these results could
be used to change the guidelines and allow routine
re-transfusion of salvaged blood as opposed to overriding
guidance in extreme emergency, and therefore allowing
cell salvage to be used for elective and emergency cases.
Even though it was not our intention to re-transfuse any
salvaged blood in this study, 500 ml was transfused to
two cases. No changes in clinical state, heart rate, or
clinical complications were noted, showing that in elective
cases unexpected large blood loss can still occur and cell
salvage can have a role to play in this situation.
This initial project acted as an exploratory study, and
after the collection of these data, we have now implemented
a comprehensive programme of cell salvage within our
Trust to all women undergoing elective Caesarean sections,
and further work is ongoing.
We conclude that one suction may be used in the obste-
tric setting, and washed ﬁltered blood from partially ﬁlled
bowls should not be re-transfused, regardless of the clini-
cal situation. To obtain maximum washing efﬁciency in
removing AF and fetal contaminants, only complete bowls
in the automatic mode should be accepted.
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